Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy.
Eur J Ophthalmol
; 18(4): 645-8, 2008.
Article
en En
| MEDLINE
| ID: mdl-18609492
ABSTRACT
PURPOSE:
To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.METHODS:
All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.RESULTS:
Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p 0.02).CONCLUSIONS:
Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades de la Coroides
/
Coroides
/
Enfermedades Vasculares Periféricas
/
Anticuerpos Monoclonales
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2008
Tipo del documento:
Article